Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8209615 | Applied Radiation and Isotopes | 2015 | 4 Pages |
Abstract
Because of its fast metabolism gadolinium as a commercial drug was not considered to be suitable for neutron capture therapy. We studied additive effect of gadolinium and boron co-administration using colony forming assay. As a result, the survival of tumor cells with additional 5Â ppm of Gd-DTPA decreased to 1/10 compared to the cells with boron only. Using gadolinium to increase the effect of BNCT instead of additional X-ray irradiation might be beneficial, as such combination complies with the short-time irradiation regimen at the accelerator-based neutron source.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
F. Yoshida, T. Yamamoto, K. Nakai, A. Zaboronok, A. Matsumura,